Park Medi World shares jumped 10% following Emkay Research's 'Buy' rating and a target price of ₹350, suggesting a 35% potential rise. Strong business model, asset efficiency, and expansion plans highlight the company's competitive edge in healthcare.
Park Medi World shares surged 10% after Emkay Research initiated a 'Buy' rating with a target price of ₹350. This implies a significant 35% upside potential for the stock. The company's robust business model, asset efficiency, and expansion plans contribute to its strong…
Market Samachar is a news aggregator. This article was originally published by mint - markets. Tap the button above to read the full story on their site.